An interventional study of Mosapride citrate and Placebo in Stomach Cancer, sponsored by Gangnam Severance Hospital. Completed at 1 site in Korea, Republic of. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2025-01-08.
Sponsored by Gangnam Severance Hospital · Not applicable, Interventional, and Treatment
"Mosapride citrate is a 5-hydroxytryptamine 4 receptor agonist, and is widely used as an agent to increase intestinal motility. Mosapride citrate has been demonstrated in in vitro and in vivo studies to increase both gastric and colon motility. In a case-control study of patients undergoing colonectomy, mosapride citrate was found to significantly reduce gas passing and defecation time.
Recently, a study reported that mosapride citrate acts on the α7nACh receptor and, consequently, suppresses the inflammatory response of macrophages, thereby suppressing the mechanism that induces paralysis after surgery.
To date, this study is intended to analyze whether mosapride citrate significantly affects the improvement of bowel movement after surgery after gastrectomy."
2,851 studies on the registry are indexed under Stomach Neoplasms; 864 are open to participants now.
This study's enrollment of 104 is above the median of 67 across 2,096 interventional studies indexed under Stomach Neoplasms.
Browse Stomach Neoplasms studies →Gangnam Severance Hospital is the lead sponsor of 141 studies on the registry; 37 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients receive placebo or mosapride citrate (5mg/T) three times a day from the first day after surgery.
Drug: Mosapride citrate
Patients receive placebo instead of mosapride citrate (5mg/T) three times a day from the first day after surgery
Drug: Placebo
Patients receive mosapride citrate (5mg/T) three times a day from the first day after surgery.
Placebo
The number of radiopaque markers transferred to the large intestine 3 days after surgery
Intestinal motility after gastrectomy
Time frame: 3 Days after surgery
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gangnam Severance Hospital